J

Johnson & Johnson

Makes prescription drugs and medical devices

General Manager Vision Care

Full-TimePosted on 10/21/2026Deadline 11/4/26
No salary listed
Expert
Bachelor's, Master's, MBA
Singapore
Hybrid
Business & Strategy

About the job

Requirements
  • A minimum of 12 years of business and commercial experience in sales and marketing is required.
  • Strong P&L management capability.
  • A customer-centric mindset and deep understanding of market and customer needs.
  • Strategic leadership with a proven track record of execution excellence.
  • Ability to lead effectively in a complex matrix organization and drive alignment toward shared objectives.
  • Demonstrated capability to drive change, transformation, and business growth.
  • Inclusive leadership style and commitment to fostering a psychologically safe work environment.
  • Strong digital acumen and AI fluency.
  • High degree of cultural agility and adaptability, with proven end-to-end P&L leadership experience.
  • Leadership experience across different business lifecycles, including high-growth, turnaround, and transformation environments.
  • Strong cross-market, preferably multi-market, and cross-functional leadership experience, coupled with a successful track record in global strategic marketing (upstream) roles.
  • Demonstrated success in go-to-market strategy development, product launches, and strategic partnership management.
Responsibilities
  • Identify and prioritize sustainable growth opportunities by market, channel, customer segment, and portfolio; evolve route-to-market and business models across direct and distributor-led markets to improve access, penetration, productivity, and profitable growth, and scale successful commercial practices across markets while adapting to local needs.
  • Own revenue, market share, gross profit, operating expenses, profitability, cash generation, and return on investment; lead annual business planning, budgeting, forecasting, resource allocation, and performance reviews.
  • Drive disciplined sales and marketing execution, including segmentation and targeting, key-account strategy, field-force effectiveness, pricing, promotion, trade investment, demand generation, and commercial excellence; establish clear metrics and operating rhythms to improve execution quality and predictability.
  • Build trusted partnerships with strategic customers, eye care professionals, key opinion leaders, channel partners, and other external stakeholders; deepen customer and consumer insights and translate them into superior experiences, professional education, advocacy, category development, and stronger brand preference.
  • Shape portfolio choices and lifecycle priorities for SEA; lead launch readiness, adoption, and commercial scale-up of global and regional innovations, ensuring clear value propositions, evidence-based education, supply readiness, and post-launch performance management.
  • Anticipate competitive, economic, regulatory, reimbursement, and channel developments; partner with relevant functions to remove access barriers, protect business continuity, manage issues and opportunities, and shape an environment that supports responsible category and market growth.
  • Select, govern, and develop distributors, E/Social Commerce, and other strategic partners through clear expectations, joint business plans, performance scorecards, capability building, inventory discipline, and regular business reviews; ensure partner activities meet commercial, quality, and compliance standards.
  • Partner with Finance, Supply Chain, Customer Service, and Commercial Operations to strengthen demand planning, service levels, inventory health, working capital, and business continuity; balance growth ambitions with disciplined execution, risk management, and cost productivity.
  • Champion the effective use of digital platforms, analytics, and AI to generate actionable insights, improve customer engagement, strengthen forecast and investment decisions, increase field productivity, and accelerate scalable commercial innovation.
  • Lead, coach, and inspire a diverse team of more than 60 employees across SEA; build an inclusive, high-performing, and psychologically safe culture with clear accountability, strong engagement, differentiated performance, critical capability development, succession depth, and a robust pipeline of future leaders.
  • Align country, cluster, APAC, and global stakeholders across Sales, Marketing, Professional Education, Commercial Operations, Finance, HR, Supply Chain, Regulatory, Quality, Medical/Clinical, Legal, Privacy, and Health Care Compliance to convert strategy into coordinated execution and resolve trade-offs at pace.
  • Ensure all business activities meet applicable laws, regulations, quality standards, company policies, and ethical requirements; model Credo-based leadership, maintain effective controls, and proactively identify, escalate, and mitigate commercial, operational, reputational, and compliance risks.
  • Lead organizational and commercial transformation across markets, simplify ways of working, build change readiness, and sustain adoption of new capabilities, operating models, and strategic initiatives while maintaining customer focus and business momentum.
Desired Qualifications
  • A minimum of 5 years of Business Unit management experience is preferred.
  • A Master of Science degree or MBA is preferred.
  • Account management, client management, commercial awareness, commercial laws, commercial management, corporate management, critical thinking, Customer Effort Score, customer retentions, developing others, inclusive leadership, leadership, market savvy, negotiation, operational excellence, pricing strategies, professional ethics, profitability analysis, and stakeholder engagement.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.